Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB4A | P04350 | 4/20 | 0.87 |
| ▸ | TUBB | P07437 | 4/20 | 0.87 |
| ▸ | TUBA3C | P0DPH7 | 4/20 | 0.87 |
| ▸ | TUBA1B | P68363 | 4/20 | 0.87 |
| ▸ | TUBA4A | P68366 | 4/20 | 0.87 |
| ▸ | TUBB4B | P68371 | 4/20 | 0.87 |
| ▸ | TUBB3 | Q13509 | 4/20 | 0.87 |
| ▸ | TUBB2A | Q13885 | 4/20 | 0.87 |
| ▸ | TUBB8 | Q3ZCM7 | 4/20 | 0.87 |
| ▸ | TUBA3E | Q6PEY2 | 4/20 | 0.87 |
| ▸ | TUBA1A | Q71U36 | 4/20 | 0.87 |
| ▸ | TUBA1C | Q9BQE3 | 4/20 | 0.87 |
| ▸ | TUBB6 | Q9BUF5 | 4/20 | 0.87 |
| ▸ | TUBB2B | Q9BVA1 | 4/20 | 0.87 |
| ▸ | TUBB1 | Q9H4B7 | 4/20 | 0.87 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.83 |
| ▸ | TSHR | P16473 | 1/20 | 0.83 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.83 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.83 |
| ▸ | P4HB | P07237 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mertansine SCHEMBL21095214 | 1.00 | TUBB4A (0.87) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Mertansine SCHEMBL24235209 | 1.00 | TUBB4A (0.87) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Mertansine SCHEMBL22762724 | 1.00 | TUBB4A (0.87) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Mertansine SCHEMBL22097295 | 1.00 | TUBB4A (0.87) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Mertansine SCHEMBL24776847 | 1.00 | TUBB4A (0.87) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Mertansine SCHEMBL24917414 | 1.00 | TUBB4A (0.87) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Mertansine SCHEMBL24823366 | 1.00 | TUBB4A (0.87) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Mertansine SCHEMBL24336892 | 1.00 | TUBB4A (0.87) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Mertansine SCHEMBL23140493 | 1.00 | TUBB4A (0.87) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Mertansine SCHEMBL22580840 | 1.00 | TUBB4A (0.87) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240067616-A1 | PEPTIDE CONJUGATES OF MICROTUBULE-TARGETING AGENTS AS THERAPEUTICS | Cybrexa 3, Inc. | 2024-02-29 | — | — | US | disclosed |
| US-11912792-B2 | Bicyclic peptide ligands specific for nectin-4 | BICYCLETX LIMITED (GB) | 2024-02-27 | — | — | US | disclosed |
| US-11912792-B2 | Bicyclic peptide ligands specific for nectin-4 | BICYCLETX LIMITED (GB) | 2024-02-27 | — | — | US | disclosed |
| US-11814447-B2 | Peptide ligands for binding to EphA2 | Bicyclerd Limited (GB) | 2023-11-14 | — | — | US | disclosed |
| US-11814447-B2 | Peptide ligands for binding to EphA2 | Bicyclerd Limited (GB) | 2023-11-14 | — | — | US | disclosed |
| US-20230340020-A1 | PEPTIDE LIGANDS FOR BINDING TO MT1-MMP | BICYCLETX LIMITED (GB) | 2023-10-26 | — | — | US | disclosed |
| US-20230340020-A1 | PEPTIDE LIGANDS FOR BINDING TO MT1-MMP | BICYCLETX LIMITED (GB) | 2023-10-26 | — | — | US | disclosed |
| US-11795218-B2 | Diagnosis and therapy of cancer involving cancer stem cells | BIONTECH AG (DE) | 2023-10-24 | — | — | US | disclosed |
| US-20230330244-A1 | NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE (NAMPT) INHIBITOR-CONJUGATES AND USES THEREOF | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2023-10-19 | — | — | US | disclosed |
| US-20230287047-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR NECTIN-4 | BICYCLETX LIMITED (GB) | 2023-09-14 | — | — | US | disclosed |
| WO-2017184956-A1 | COMPOUNDS AND METHODS FOR TARGETING HSP90 | DUKE UNIVERSITY (US) | 2017-10-26 | — | — | WO | disclosed |
| US-20170072065-A1 | ANTI-EGFR ANTIBODIES AND ANTIBODY DRUG CONJUGATES | ABBVIE INC. | 2017-03-16 | — | — | US | disclosed |
| US-9480754-B2 | Phospholipid ether analogs as cancer-targeting drug vehicles | CELLECTAR BIOSCIENCES, INC. (US) | 2016-11-01 | — | — | US | disclosed |
| US-20160228564-A1 | Phospholipid Ether Analogs as Cancer-Targeting Drug Vehicles | CELLECTAR BIOSCIENCES INC (US) | 2016-08-11 | — | — | US | disclosed |
| US-20160159901-A1 | DIAGNOSIS AND THERAPY OF CANCER INVOLVING CANCER STEM CELLS | ASTELLAS PHARMA INC. (JP) | 2016-06-09 | — | — | US | disclosed |
| US-20160159901-A1 | DIAGNOSIS AND THERAPY OF CANCER INVOLVING CANCER STEM CELLS | ASTELLAS PHARMA INC. (JP) | 2016-06-09 | — | — | US | disclosed |
| US-9345718-B1 | Phospholipid ether analogs as cancer-targeting drug vehicles | CELLECTAR BIOSCIENCES, INC. (US) | 2016-05-24 | — | — | US | disclosed |
| US-20160136290-A1 | Phospholipid Ether Analogs as Cancer-Targeting Drug Vehicles | CELLECTAR BIOSCIENCES, INC. | 2016-05-19 | — | — | US | disclosed |
| US-20160136190-A1 | Phospholipid Ether Analogs as Cancer-Targeting Drug Vehicles | CELLECTAR BIOSCIENCES, INC. | 2016-05-19 | — | — | US | disclosed |
| US-20160136190-A1 | Phospholipid Ether Analogs as Cancer-Targeting Drug Vehicles | CELLECTAR BIOSCIENCES, INC. | 2016-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11795218-B2 | Diagnosis and therapy of cancer involving cancer stem cells | EPCAM, CD44, JUP | TUBB4A 329/4885TUBB 865/4885TUBA3C 406/4885 |
| US-20230287047-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR NECTIN-4 | NECTIN4, VCAM1, SIGLEC7 | TUBB4A 1006/4885TUBB 1848/4885TUBA3C 815/4885 |
| US-20170072065-A1 | ANTI-EGFR ANTIBODIES AND ANTIBODY DRUG CONJUGATES | EGFR, ERBB2, ERBB3 | TUBB4A 337/4885TUBB 282/4885TUBA3C 173/4885 |
| US-20230330244-A1 | NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE (NAMPT) INHIBITOR-CONJUGATES AND USES THEREOF | NAMPT, NAPRT, NNT | TUBB4A 2103/4885TUBB 1602/4885TUBA3C 3747/4885 |
| US-11814447-B2 | Peptide ligands for binding to EphA2 | EPHA2, CD2BP2, LNPEP | TUBB4A 1722/4885TUBB 1365/4885TUBA3C 577/4885 |
| US-20230340020-A1 | PEPTIDE LIGANDS FOR BINDING TO MT1-MMP | MMP11, MMP3, ANPEP | TUBB4A 1268/4885TUBB 1256/4885TUBA3C 539/4885 |
| US-20160136190-A1 | Phospholipid Ether Analogs as Cancer-Targeting Drug Vehicles | PHOSPHO1, MCL1, LPCAT3 | TUBB4A 560/4885TUBB 655/4885TUBA3C 726/4885 |
| US-20160228564-A1 | Phospholipid Ether Analogs as Cancer-Targeting Drug Vehicles | PHOSPHO1, MCL1, LPCAT3 | TUBB4A 560/4885TUBB 655/4885TUBA3C 726/4885 |
| US-11912792-B2 | Bicyclic peptide ligands specific for nectin-4 | NECTIN4, VCAM1, SIGLEC7 | TUBB4A 1006/4885TUBB 1848/4885TUBA3C 815/4885 |
| US-20240067616-A1 | PEPTIDE CONJUGATES OF MICROTUBULE-TARGETING AGENTS AS THERAPEUTICS | MAP4, MAP2, TUBB3 | TUBB4A 10/4885TUBB 9/4885TUBA3C 13/4885 |
| US-20160159901-A1 | DIAGNOSIS AND THERAPY OF CANCER INVOLVING CANCER STEM CELLS | EPCAM, CD44, JUP | TUBB4A 322/4885TUBB 830/4885TUBA3C 386/4885 |
| US-20160136290-A1 | Phospholipid Ether Analogs as Cancer-Targeting Drug Vehicles | PHOSPHO1, MCL1, LPCAT3 | TUBB4A 560/4885TUBB 655/4885TUBA3C 726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.